Some biotech CEOs find themselves out of jobs following a buyout. Not Mary Kerr.
In fact, after Bayer dished out $425 million in cash to buy KaNDy Therapeutics and its menopause treatment last August — which was spun out from NeRRe Therapeutics and run by that exact same team — her entire crew quickly got back to work.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,